These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 30045977)

  • 1. LRRK2 activation in idiopathic Parkinson's disease.
    Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
    Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 and idiopathic Parkinson's disease.
    Rocha EM; Keeney MT; Di Maio R; De Miranda BR; Greenamyre JT
    Trends Neurosci; 2022 Mar; 45(3):224-236. PubMed ID: 34991886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single molecule array measures of LRRK2 kinase activity in serum link Parkinson's disease severity to peripheral inflammation.
    Yuan Y; Li H; Sreeram K; Malankhanova T; Boddu R; Strader S; Chang A; Bryant N; Yacoubian TA; Standaert DG; Erb M; Moore DJ; Sanders LH; Lutz MW; Velmeshev D; West AB
    Mol Neurodegener; 2024 Jun; 19(1):47. PubMed ID: 38862989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.
    Liu J; Li T; Thomas JM; Pei Z; Jiang H; Engelender S; Ross CA; Smith WW
    Hum Mol Genet; 2016 Feb; 25(4):672-80. PubMed ID: 26744328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.
    Xu E; Boddu R; Abdelmotilib HA; Sokratian A; Kelly K; Liu Z; Bryant N; Chandra S; Carlisle SM; Lefkowitz EJ; Harms AS; Benveniste EN; Yacoubian TA; Volpicelli-Daley LA; Standaert DG; West AB
    Mol Neurodegener; 2022 Jan; 17(1):7. PubMed ID: 35012605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
    López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
    J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
    Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
    eNeuro; 2019; 6(6):. PubMed ID: 31685675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
    Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
    Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
    Wang S; Unnithan S; Bryant N; Chang A; Rosenthal LS; Pantelyat A; Dawson TM; Al-Khalidi HR; West AB
    Mov Disord; 2022 Jul; 37(7):1454-1464. PubMed ID: 35521944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.